Search for Clinical Trial Results

Sponsored By

Philadelphia Chromosome - 23 Studies Found

Status Study
Recruiting Study Name: A Phase III Randomized Trial of the Reduction of Chemotherapy in Philadelphia Chromosome-positive ALL of Young Adults
Condition: Philadelphia Chromosome Positive Adult Acute Lymphoblastic Leukemia
Date: 2015-11-19
Interventions:
  • Drug: Nilotinib 400 mg/12h per
Suspended Study Name: Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+)
Condition: Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+)
Date: 2010-10-15
Interventions: Drug: Imatinib Mesylate patient will receive Imatinib (Glivec®), 300 mg/m²/day, per oral, in c
Suspended Study Name: Phase II Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Chronic Myeloid Leukemia (CML) Philadelphia Chromosome-positive (Ph+)
Condition: Chronic Myeloid Leukemia (CML) With Philadelphia Chromosome-positive (Ph+)
Date: 2010-10-14
Interventions: Drug: Imatinib Mesylate Patient will receive Imatinib Mesylate, continuous-use, 260 mg/m2/day dose, maxi
Terminated Study Name: Entinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Condition:
  • Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia
  • Drug: entinostat Given PO
Terminated Study Name: TKI Therapy Based on Molecular Monitoring in Allogeneic-HSCT Recipients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
Condition:
  • Philadelphia Chromosome Positive Acute Lymphocytic Leukemia
  • Ste
    Date: 2013-06-14
    Interventions: Drug: TKI Imatinib will be given for patients without BCR/ABL mutations with a dose of 400mg/d or 600mg/
Recruiting Study Name: Intravenous Erwinia Chrysanthemi Asparaginase in Patients With Newly Diagnosed Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Aged 60 Years or Older
Condition:
  • Acute Lymphoblastic Leukemia (ALL)
  • Newly Diagnosed Philadelphia Chromo
    Date: 2016-01-05
    Interventions: Drug: Erwinia Chrysanthemi asparaginase
Completed Study Name: Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response
Condition:
  • Philadelphia Chromosome Positive
  • Chronic Myelogenous Leukemia i
    Date: 2010-01-05
    Interventions: Drug: Nilotinib 400 mg BID Other Name: AMN107
Completed Study Name: Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome & /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase
Condition: CML in Chronic Phase
Date: 2010-02-01
Interventions: Drug: Nilotinib Nilotinib was supplied by Novartis as 150 mg hard gelatin capsules in bottles. Nilotinib
No longer available Study Name: Compassionate Use Ponatinib
Condition:
  • Philadelphia Chromosome Positive (Ph+) Leukemias
  • Chronic Myeloi
    Date: 2012-03-06
    Interventions: Drug: Ponatinib Patients will receive Ponatinib 45 mg by mouth as a single daily dose on an empty stomac
Completed Study Name: Bioequivalence And Food Effect Study Of Bosutinib In Healthy Subjects
Condition: Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia (CML)
Date: 2011-06-07
Interventions:
  • Drug: Bosutinib 5 clinical 100
Next >>>